SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Lab inches up on re-launching Buprenorphine and Naloxone Sublingual Film

21 Feb 2019 Evaluate

Dr. Reddy’s Laboratories is currently trading at Rs. 2531.10, up by 7.40 points or 0.29% from its previous closing of Rs. 2523.70 on the BSE.

The scrip opened at Rs. 2530.10 and has touched a high and low of Rs. 2554.90 and Rs. 2521.00 respectively. So far 6930 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2875.00 on 04-Feb-2019 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2685.00 and Rs. 2065.30 respectively. The current market cap of the company is Rs. 41908.78 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.67% and 13.94% respectively.

Dr. Reddy's Laboratories along with its subsidiaries, has re-launched Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the United States market.

The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit concluding that Indivior had not shown that it is likely to succeed on its claim that Dr. Reddy's product infringes US Patent.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1236.95 1.55 (0.13%)
20-Apr-2026 09:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.80
Dr. Reddys Lab 1236.95
Cipla 1237.00
Zydus Lifesciences 940.75
Lupin 2338.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×